Upstream Processing

Webinar Date/Time: Tue, Mar 4, 2025 11:00 AM EST

Webinar Date/Time: Thu, Dec 12, 2024 11:00 AM EST

Under a £15.7 million (US$20.7 million) investment, SEKISUI has expanded its UK site for clinical-grade drug substance manufacturing.

With financing led by OrbiMed, Novo Holdings, and Jeito Capital, Alentis Therapeutics will develop a pipeline of Claudin-1-targeted ADCs to treat solid tumors.

Webinar Date/Time: Thu, Nov 7, 2024 11:00 AM EDT

Space-time yield is a critical metric for comparison of upstream biomanufacturing processes and can be useful in reducing commercial production costs.

Webinar Date/Time: Thu, Oct 31, 2024 11:00 AM EDT

Webinar Date/Time: Wed, Oct 16, 2024 11:00 AM EDT

Stable cell line development can benefit from applying integrated analytical technologies.

Automation technologies used in the development and manufacture of biopharmaceuticals continue to evolve, providing the potential for reduced costs and time.

Optimizing AAV vector manufacturing will be necessary to meet anticipated future market demand.

Improving the flexibility of cell line development through utilization of platform approaches and suitable partnerships can reduce potential bottlenecks in the development pathway of novel biologics.

AGC Biologics has completed an expansion at its Copenhagen, Denmark, site, which doubles its bioreactor capacity for mammalian-based cell culture.

Using a multi-pronged strategy to find optimum, tailored formulations is best.

This commentary summarizes the derivation of clonal HEK293 suspension cell lines, selection of clones for rAAV production, and design of experiments-based optimization strategies for characterization of one clonal isolate for high yield rAAV manufacture. Data shown provides proof of concept for the success of this strategy, its applicability for manufacturing different rAAV serotypes and lays the foundation of further clonal cell line characterization for scale up of production.

Global product manager at Cytiva, Eric Corti, discusses the challenges with designing a new single-use mixing system that ensures leak-free fluid handling operations at INTERPHEX 2024.

This investment will bolster the company’s large-scale cell culture CDMO business at its planned Fujifilm Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina.

Despite a growing trend toward single-use bioreactors, stainless-steel retains its relevance for certain products.

A tidal wave of questions floats the need for more upstream automation.

Challenges in fermentation can be addressed through equipment changes, facility design, and process development.

The milestone approval of a gene-edited therapeutic paves the way for gene-editing technologies.

Abzena has launched its AbZelect platforms, designed for improving cell line development.

The authors give an overview of scaling approaches and present good scaling practices for the biopharma industry.

Both adherent and suspension cell culture approaches have their pros and cons, which must be considered for process development.

Tome Bioscience is facilitating the transition in biology from the editing phase to the cut-and-paste phase.

Re-evaluating the basics of mAb production may be beneficial for the biopharma industry as a whole.

The construction of Gritgen’s GMP facility strictly adheres to the global current GMP (CGMP) standards and complies with the regulatory guidelines of authoritative agencies including the National Medical Products Administration (NMPA), FDA, and the European Medicines Agency (EMA).

Using a systematic approach and achieving run-to-run consistency are essential.

Process and bioreactor performance are directly impacted by real-time monitoring capabilities.

Sartorius’ Biostat STR now incorporates Repligen’s XCell ATF hardware.